H
Hao Xie
Researcher at Mayo Clinic
Publications - 61
Citations - 910
Hao Xie is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Cancer & Colorectal cancer. The author has an hindex of 15, co-authored 52 publications receiving 609 citations. Previous affiliations of Hao Xie include Cleveland Clinic Lerner College of Medicine & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Review of cranial radiotherapy-induced vasculopathy.
TL;DR: The preclinical findings regarding the pathophysiology of late radiation-induced vascular damage are reviewed, and the clinical incidence and risk factors for each type of vasculopathy are discussed.
Journal ArticleDOI
Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century
Siddhartha Yadav,Dhauna Karam,Irbaz Bin Riaz,Hao Xie,Urshila Durani,Narjust Duma,Karthik V. Giridhar,Tina J. Hieken,Judy C. Boughey,Robert W. Mutter,John R. Hawse,Rafael E. Jimenez,Fergus J. Couch,Roberto A. Leon-Ferre,Kathryn J. Ruddy +14 more
TL;DR: Male breast cancer (MBC) is a rare disease for which there is limited understanding of treatment patterns and prognostic factors and there is a need to understand more about how these patterns are changed over time.
Journal ArticleDOI
Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis.
Siddhartha Yadav,Hao Xie,Irbaz Bin-Riaz,Prabin Sharma,Urshila Durani,Gaurav Goyal,Bijan J. Borah,Mitesh J. Borad,Rory L. Smoot,Lewis R. Roberts,Ronald S. Go,Robert R. McWilliams,Amit Mahipal +12 more
TL;DR: In this article, the authors used the National Cancer Database (NCD) to identify patients who underwent surgery and chemotherapy for stage I-III cholangiocarcinoma between 2006 and 2014.
Journal ArticleDOI
Recent Advances in the Clinical Targeting of Hedgehog/GLI Signaling in Cancer.
TL;DR: Pre-clinical evidence supporting the suitability of targeting this signaling pathway in cancers is summarized, and published and ongoing clinical trial data on single agent or combination therapeutic strategies, targeting Hedgehog/GLI signaling pathway, in both advanced solid tumors and hematologic malignancies are provided.
Journal ArticleDOI
Treatment of cerebral radiation necrosis with bevacizumab: the Cleveland clinic experience.
Neda H. Sadraei,Saurabh Dahiya,Samuel T. Chao,Erin S. Murphy,Erin S. Murphy,Kwabena Osei-Boateng,Hao Xie,John H. Suh,David M. Peereboom,Glen Stevens,Manmeet Ahluwalia +10 more
TL;DR: Bevacizumab treatment results in excellent clinical and radiologic response in patients with RN caused by common forms of radiation therapy, and the safety profile of bevacIZumab use in RN is acceptable.